- Home
- VTGN vs NERV Comparison
VTGN vs NERV Comparison
Compare VTGN & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VTGN | NERV |
|---|---|---|
| Founded | 1998 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.8M | 29.2M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | VTGN | NERV |
|---|---|---|
| Price | $0.66 | $4.45 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 3 | 1 |
| Target Price | $0.90 | ★ $4.00 |
| AVG Volume (30 Days) | ★ 6.2M | 55.2K |
| Earning Date | 02-12-2026 | 02-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $721,000.00 | N/A |
| Revenue This Year | $54.26 | N/A |
| Revenue Next Year | $478.23 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.63 | $1.15 |
| 52 Week High | $5.14 | $12.46 |
Technical Indicators
Market Signals| Indicator | VTGN | NERV |
|---|---|---|
| Relative Strength Index (RSI) | 24.05 | 57.09 |
| Support Level | $0.63 | $3.82 |
| Resistance Level | $0.77 | $4.86 |
| Average True Range (ATR) | 0.06 | 0.28 |
| MACD | 0.04 | 0.05 |
| Stochastic Oscillator | 17.96 | 55.77 |
Price Performance
Historical ComparisonAbout VTGN VistaGen Therapeutics Inc.
Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on deep understanding of nose-to-brain neurocircuitry.
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.